Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (4078)	7/9/1998 12:55:00 PM
From: Anthony Wong	Respond to of 9523

In a Bloomberg article about Abbott Labs: Abbott Laboratories, one of the world's biggest makers of medical tests and drugs, said second-quarter profit rose 12 percent amid more competition for its biggest medicine, the antibiotic Biaxin. Biaxin faces competition from Pfizer's Zithromax and Trovan antibiotics. Trovan sales started earlier this year. Message 5143390

To: Anthony Wong who wrote (4078)	7/9/1998 2:10:00 PM
From: zurdo	Read Replies (1) \| Respond to of 9523

Anthony and everybody, PFE has reached 115, but can't maintain the push beyond that level (yet)...Every time it reaches 115, there is tremendous surge of selling pressure...Somebody is certainly fighting the upward push...It is definitely THE TEST...